

TRADEMARK ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	ASSIGNS THE ENTIRE INTEREST AND THE GOODWILL		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
Nexell Therapeutics Inc.		01/27/2003	CORPORATION: DELAWARE
RECEIVING PARTY DATA			
Name:	BioScience 2002 LLC		
Street Address:	One Baxter Parkway		
Internal Address:	DF2-1W		
City:	Deerfield		
State/Country:	ILLINOIS		
Postal Code:	60015		
Entity Type:	LIMITED LIABILITY COMPANY: DELAWARE		
PROPERTY NUMBERS Total: 1			
Property Type	Number	Word Mark	
Registration Number:	1466274	LIFECCELL	
CORRESPONDENCE DATA			
Fax Number:	2249483880		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent via US Mail.</i>			
Phone:	2249484720		
Email:	sue_semaszczuk@baxter.com		
Correspondent Name:	Jeffrey C. Nichols		
Address Line 1:	One Baxter Parkway		
Address Line 2:	DF 2-1W		
Address Line 4:	Deerfield, ILLINOIS 60015		
NAME OF SUBMITTER:	Jeffrey C. Nichols		
Signature:	/Jeffrey C Nichols/		
Date:	07/20/2012		

CH \$40.00 1466274

TRADEMARK

Total Attachments: 15

source=Nexell to Bio2002#page1.tif
source=Nexell to Bio2002#page2.tif
source=Nexell to Bio2002#page3.tif
source=Nexell to Bio2002#page4.tif
source=Nexell to Bio2002#page5.tif
source=Nexell to Bio2002#page6.tif
source=Nexell to Bio2002#page7.tif
source=Nexell to Bio2002#page8.tif
source=Nexell to Bio2002#page9.tif
source=Nexell to Bio2002#page10.tif
source=Nexell to Bio2002#page11.tif
source=Nexell to Bio2002#page12.tif
source=Nexell to Bio2002#page13.tif
source=Nexell to Bio2002#page14.tif
source=Nexell to Bio2002#page15.tif



ASSIGNMENT

WHEREAS, at the meeting of the Board of Directors of Nexell Therapeutics Inc., a Delaware corporation (“Nexell” or the “Company”), on October 16, 2002, the Board of Directors adopted a Plan of Complete Liquidation and Dissolution (the “Plan”), which Plan was authorized and approved by written consent of the holder of a majority of Nexell’s outstanding common stock on November 22, 2002;

WHEREAS, paragraph 3(c) of the Plan provides for the establishment of a contingency reserve in cash and/or property (the “Contingency Reserve”) to satisfy claims, obligations and expenses of Nexell as described in paragraph 3(c), and further provides that any unexpended amounts remaining in the Contingency Reserve shall be transferred to the liquidating trust described in Section 6 of the Plan no later than December 31, 2002;

WHEREAS, paragraph 3(f) of the Plan provides for the distribution of any unexpended and unencumbered balance of the Contingency Reserve to be made in accordance with paragraph 3(e)(ii) of the Plan;

WHEREAS, paragraph 3(e)(i) of the Plan provides for a distribution of \$0.05 per share of common stock, but not in excess of \$872,026 in the aggregate, in cash to the record holders (excluding BioScience 2002 LLC) of outstanding common stock on the record date for such distribution set by the Board of Directors (the “Common Stock Distribution”);

WHEREAS, paragraph 3(e)(ii) of the Plan provides that the balance of the cash and other assets of Nexell (other than any unexpended portion of the Contingency Reserve and the Common Stock Distribution) shall be distributed to the record holder of the Series A Preferred

Stock and Series B Preferred Stock of Nexell on the record date set for such distribution by the Board of Directors (the "Preferred Stock Distribution");

WHEREAS, Section 6 of the Plan provides that Nexell may transfer to a liquidating trustee under a liquidating trust agreement any assets not previously distributed to or for the benefit of the stockholders of Nexell, and that any such conveyance of assets to such trustee shall be deemed a distribution of property and assets by Nexell to the stockholders holding a beneficial interest under the trust agreement; and paragraph 3(d) of the Plan provides that any cash or assets of Nexell not previously distributed to stockholders be transferred to the liquidating trust described in Section 6 of the Plan no later than December 31, 2002;

WHEREAS, the sole Director of Nexell (i) confirmed the close of business on December 18, 2002 as the record date for the Common Stock Distribution, (ii) declared the Common Stock Distribution to record holders (excluding BioScience 2002 LLC) of outstanding common stock on such record date, and (iii) determined that the Common Stock Distribution be made on or about December 23, 2002;

WHEREAS, the sole Director of Nexell (i) confirmed the close of business on December 18, 2002 as the record date for the Preferred Stock Distribution, (ii) declared the Preferred Stock Distribution to the record holder of the Series A Preferred Stock and the Series B Preferred Stock of Nexell on such record date, and (iii) determined that the Preferred Stock Distribution be made by transferring the assets that are the subject of the Preferred Stock Distribution to the Nexell Therapeutics Liquidating Trust (the "Trust") established pursuant to the terms of the Liquidating Trust Agreement dated December 24, 2002 between Nexell and Avidity Partners, LLC, as Trustee (the "Trust Agreement");

WHEREAS, on December 24, 2002, all of the assets of Nexell, other than the Common Stock Distribution, were transferred to the Trustee, on behalf of the Trust, pursuant to the terms of the Trust Agreement;

WHEREAS, pursuant to Section 4.2(b) of the Trust Agreement the Trustee desires to transfer the assets identified on Schedule 1 attached to this Assignment and incorporated herein by this reference (the "Assets"), to BioScience 2002 LLC ("BioScience"), the sole record holder of the Series A Preferred Stock and Series B Preferred Stock of Nexell at the close of business on December 18, 2002; and

WHEREAS, pursuant to Schedule D of the Plan BioScience will assume all of Nexell's liabilities identified on Schedule 2 attached to this Assignment and incorporated herein by this reference, but only to the extent arising after the date hereof (the "Liabilities").

NOW, THEREFORE, in consideration of good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties hereto agree as follows:

1. The Trustee, on behalf of the Trust, hereby transfers, sells and assigns to and vests in BioScience, all of its right, title and interest in the Assets (including, without limitation, all rights, privileges, powers, franchises and immunities, contractual or otherwise in connection therewith). BioScience hereby accepts such assignment, conveyance and transfer of the Assets and BioScience hereby assumes all of the Liabilities. Notwithstanding anything in this Assignment to the contrary, the parties hereto acknowledge and agree that the Assets shall not include (i) \$1,670,818 in cash and an estimated \$434,084 of receivables comprised of royalties, refunds, deposits and credits, which together shall be retained by the Trustee as the remaining


Contingency Reserve, and (ii) any and all insurance policies that had been previously owned by Nexell.

2. The parties hereto hereby agree to cooperate as may be reasonably required to effect fully the assignment and assumption and each other transaction contemplated by this Assignment and to take all actions and execute all documents and instruments as may be reasonably requested by the other party hereto in connection therewith.

3. This Assignment shall be governed by the laws of the State of Delaware. This Assignment may be executed in counterparts, each of which when so executed and delivered shall be deemed an original, and such counterparts together shall constitute only one original.

Executed this 27th day of January, 2003.

Avidity Partners, LLC, as Trustee of the Nexell
Therapeutics Liquidating Trust

By:  _____
John J. Ray, III, Principal

BIOSCIENCE 2002 LLC

By _____

Contingency Reserve, and (ii) any and all insurance policies that had been previously owned by Nexell.

2. The parties hereto hereby agree to cooperate as may be reasonably required to effect fully the assignment and assumption and each other transaction contemplated by this Assignment and to take all actions and execute all documents and instruments as may be reasonably requested by the other party hereto in connection therewith.

3. This Assignment shall be governed by the laws of the State of Delaware. This Assignment may be executed in counterparts, each of which when so executed and delivered shall be deemed an original, and such counterparts together shall constitute only one original.

Executed this 27th day of January, 2003.

Avidity Partners, LLC, as Trustee of the Nexell
Therapeutics Liquidating Trust

By: _____
John J. Ray, III, Principal

BIOSCIENCE 2002 LLC

By:  _____
Victor W. Schmitt

Schedule 1

Assets and Properties

All of Nexell's and the Trustee's right, title and interest in and to the following assets are hereby transferred to BioScience:

SUBSIDIARIES:

- Nexell of California, Inc. ("NCI") – 100 shares of common stock

INTELLECTUAL PROPERTY – all of Nexell's and the Trustee's right, title and interest in and to any intellectual property, including the intellectual property described below.

COPYRIGHTS

TRADEMARKS – including, without limitation, all trademarks listed in Exhibit A attached hereto and incorporated herein by reference.

PATENTS – including, without limitation, all patent and patent applications listed in Exhibit B attached hereto and incorporated herein by reference, but excluding Hypericin technology and U.S. Patent 6001882 and related "Know How."

TRADE SECRETS AND OTHER INTANGIBLES

OTHER

Assets associated with VM301 wound healing compound including, without limitation, all assets acquired by Nexell in May 1997 pursuant to its acquisition agreement with OsteoArthritis Sciences Liquidation Trust.

WEBSITE.URL

BOOKS AND RECORDS

- ALL BOOKS AND RECORDS OF NEXELL THERAPEUTICS INC. AND ITS SUBSIDIARIES AND AFFILIATES, INCLUDING CLINICAL OR PATIENT RECORDS

OTHER:

- Asset Purchase Agreement dated October 10, 1997 by and among Baxter Healthcare Corporation, the Company and NCI
- Acquisition Agreement dated February 18, 1999 by and among Baxter Healthcare Corporation, the Company and NCI

- Asset Purchase Agreement dated as of August 3, 2001 among the Company, NCI and Baxter Healthcare Corporation

AGREEMENTS OF INNOVIR LABORATORIES, INC. WHICH SUBSEQUENTLY WERE TRANSFERRED AND ASSIGNED TO NEXELL:

- Warrant to Purchase Common Shares of Stock of Ribozyme Pharmaceuticals, Inc. dated August 13, 1999 between Ribozyme Pharmaceuticals, Inc. and Innovir Laboratories, Inc.

Schedule 2
Liabilities, Debts & Obligations

BioScience hereby assumes the obligations and liabilities of Nexell (and of Innovir Laboratories, Inc. transferred to Nexell) but not of NCI arising from and after the date hereof under the following agreements:

Asset Purchase Agreement dated October 10, 1997 by and among Baxter Healthcare Corporation, the Company and NCI

Acquisition Agreement dated February 18, 1999 by and among Baxter Healthcare Corporation, the Company and NCI

Asset Purchase Agreement dated as of August 3, 2001 among the Company, NCI and Baxter Healthcare Corporation

Warrant to Purchase Common Shares of Stock of Ribozyme Pharmaceuticals, Inc. dated August 13, 1999 between Ribozyme Pharmaceuticals, Inc. and Innovir Laboratories, Inc.

NEXELL THERAPEUTICS INC.
Trademark Portfolio

OWD Docket No.	Mark	Country	Class	Goods	Serial No.	Filing Date	Reg. No.	Reg. Date	status	due date	Expiration Date	Assign Status
16635-46	SOLEX	Benelux	10	Medical apparatus and instruments, namely cell separation and selection devices	836.061	10/25/94	563.415	10/25/94	10/25/04 - Taxes Due	10/25/04	10/25/04	Nexell
16635-46	SOLEX	CTM	9&10	Medical Products; namely cell separation and selection devices	73056	4/1/96	73056	08/23/99	04/01/06 - Taxes Due	4/1/06	04/01/06	Nexell
16635-46	SOLEX	France	10	Medical Products; namely cell separation and selection devices	94542107	10/26/94	94542107	10/26/94	10/25/04 - Taxes Due	10/25/04	10/25/04	Nexell
16635-46	SOLEX	Germany	10	Medical Products; namely cell separation and selection devices	B103436	10/29/94	2 909 054	07/13/95	10/29/04 - Taxes Due	10/29/04	10/29/04	Nexell
16635-46	SOLEX	Greece	10	Medical Products; namely cell separation and selection devices	123730	10/19/95	123730		tax due	10/19/05	10/19/05	Nexell
16635-46	SOLEX	Israel	10	Medical Products; namely cell separation and selection devices	97586	3/16/95	97586	12/03/96	03/15/02 - Taxes Due After 2002, taxes due every 14 years	3/15/02	Not limited	Nexell
16635-46	SOLEX	Italy	10	Medical Products; namely cell separation and selection devices	RM94C/005252	11/30/94	690794	10/21/96	11/30/04 - Taxes Due	11/30/04	11/30/04	Assignme nt to f/a
16635-46	SOLEX	Japan	9	Medical Products; namely cell separation and selection devices	8-116462	10/14/96	4187290	09/11/98	09/11/08 - Taxes Due	9/11/08	9/11/2008	Nexell
16635-46	SOLEX	Poland	10	Medical Products; namely cell separation and selection devices	Z-146461	5/5/95	101299	09/04/98	05/05/05 - Taxes Due	5/5/05	05/05/05	Assignme nt document s to f/a
16635-46	SOLEX	Portugal	10	Medical Products; namely cell separation and selection devices	304844	10/28/94	304844	10/10/95	renewal due 10/10/05	10/10/05	10/10/05	Nexell
16635-46	SOLEX	Spain	10	Medical Products; namely cell separation and selection devices	1928653	10/28/94	1928653	12/05/95	10/31/04	13/31/04	10/28/04	Assignme nt paperwork sent to f/a
16635-46	SOLEX	Turkey	10	Medical Products; namely cell separation and selection devices	5299/95	6/5/95			ABANDONED	//		
16635-46	SOLEX	UK	10	Medical and surgical apparatus and instruments; cell preparation and selection devices; parts and fittings for all the aforesaid goods	1589025	10/26/94	1589025	10/26/94	10/26/01 - Taxes Due	10/26/01	10/26/01	Nexell
16635-46	SOLEX	US	10	Medical Products; namely cell separation and selection devices	74/425,321	8/13/93	1,836,688	05/17/94	05/17/04 - Taxes Due	5/17/04	05/17/04	Nexell
16635-47	MAXSEP	CTM	9&10	Medical Device, namely a magnetic separator for use in selectively separating cells from a heterogeneous cell composition	71472	4/1/96	71472	07/24/98	07/24/08 - Taxes Due	7/24/08	07/24/08	Nexell

TRADEMARK
REEL: 004826 FRAME: 0513

NEXELL THERAPEUTICS INC.
Trademark Portfolio

OWD Docket No.	Mark	Country	Class	Goods	Serial No.	Filing Date	Reg. No.	Reg. Date	status	due date	Expiration Date	Assign Status
16635-47	MAXSEP	US	10	Medical Device, namely a magnetic separator for use in selectively separating cells from a heterogeneous cell composition	74/433,020	9/7/93	1,959,191	02/27/96	02/27/02 - 8 & 15 Affidavit + Fees Due 02/27/06 - Taxes Due	2/27/02	02/27/06	Nexell
16635-48	PR34+	CTM	1,5,10	Medical products, namely, stem cell releasing agent	70888	4/1/96	70888	04/20/98	04/20/08 - Taxes Due	4/20/08	04/20/08	Nexell
16635-48	PR34+	US	5	Medical products, namely, clinical preparations for clinical or medical laboratory use, namely, peptides for use in releasing cells from solid matrices	75/558677	9/24/98			Published 4/3/01; awaiting registration	10/3/01		Nexell
16635-49	LIFECCELL	Chile	10	Tissue culture flask	295,693	12/30/94	453,515	11/29/95	11/29/05 - Taxes Due	11/29/05	11/29/05	Assignme nt sent to f/a
16635-49	LIFECCELL	US	10	Medical apparatus, namely, cell culturing tissue flask with septum and bottle caps, hangers, hooks, plasma extractor, tube stripper, hand sealer [slips] * clips * and coupler	73/646,754	2/26/87	1,466,274	11/24/87	11/24/07 - Taxes Due	11/24/07	11/24/07	Nexell
16635-50	CRYOCYTE PACK	US	10	Disposable plastic bag with outlet port and cap for component freezing, storing and transfusion of platelets, plasma and other blood portions	371193	09/21/70	975,998	01/01/74	01/01/04 - Taxes Due	1/1/04	01/01/04	assignme nt cm
16635-51	X-FOLD	CA	10	Medical devices, namely, plastic bag for growing cultures	898165	12/1/98			resp to OA due 1/1/02 (need to forward certified copy of the US registration when issued)	1/1/02		Nexell
16635-51	X-FOLD	CTM	5,10	Medical devices, namely, plastic bag for growing cultures	1003334	12/1/98			registered; renewal due 12/30/08	12/30/08		Nexell
16635-51	X-FOLD	JP	5,10	Medical devices, namely, plastic bag for growing cultures	10-1106659	12/10/98	4405962	08/04/00	issued; renewal 8/4/10	2/4/10		Nexell
16635-51	X-FOLD	US	10	Medical devices, namely, plastic bag for growing cultures	75/501642	6/12/98			resp to oa due 9/10/01	9/10/01		Nexell
16635-54	Nexell Therapeutics Inc	EC	5,10,42	Therapeutic Agents...	900266				Awaiting opposition response from Heisinn Healthcare SA	2/14/02		Nexell
16635-54	Nexell Therapeutics Inc	Japan	5,10,42	Therapeutic Agents	10/68184	8/4/98	4370331	03/24/00	registration renewal due 3/24/2010	3/24/10	03/24/10	Nexell

NEXELL THERAPEUTICS INC.
Trademark Portfolio

OWD Docket No.	Mark	Country	Class	Goods	Serial No.	Filing Date	Reg. No.	Reg. Date	status	due date	Expiration Date	Assign Status
16635-54	Nexell Therapeut ics Inc	US	5, 10, 42	Therapeutic Agents...	75/432103	2/7/98	2,453,487	05/22/01	8 & 15 due	5/22/06	05/22/11	Nexell
16635-55	NEXELL Logo	Australia	5, 10 42	Therapeutic Agents	804744	8/23/99	804744	08/23/99	renewal	8/23/09	08/23/09	Nexell
16635-55	NEXELL Logo	Canada	5, 10	Therapeutic Agents	1026583	8/23/99			response to oa to f/a 3/8; status	3/9/02		Nexell
16635-55	NEXELL Logo	CTM	5, 10 42	Therapeutic Agents	1299262	9/6/99			opposition with Helsinki; status	3/3/02		Nexell
16635-55	NEXELL Logo	Japan	5, 10 42	Therapeutic Agents	11-76155	9/29/99			Filing receipt for Priority documents filed with JPO dated 09/29/99; has not been examined, expect OA 3/1/01	3/1/01		Nexell
16635-55	NEXELL Logo	US	5	Therapeutic Agents	75/645383	2/22/99			stmt of use due 9/6/01	9/6/01		Nexell
16635-58	Nexell	Australia	5, 10 42	Therapeutic devices for the separation, selection, and/or modification of cells, chemical products and reagents, biological products and biological by-products, biological tissue and cells intended for subsequent implantation, or diagnostic or therapeutic use.	804743	8/23/99			Response to Examiner's Report filed on 02/11/00; status			Nexell
16635-58	Nexell	Canada	5, 10	Therapeutic devices for the separation, selection, and/or modification of cells, chemical products and reagents, biological products and biological by-products, biological tissue and cells intended for subsequent implantation, or diagnostic or therapeutic	1028725	9/13/99			response to oa to f/a 3/8; status	3/9/02		Nexell
16635-58	Nexell	US	10	Therapeutic devices for the separation, selection, and/or modification of cells, chemical products and reagents, biological products and biological by-products, biological tissue and cells intended for subsequent implantation, or diagnostic or therapeutic use.	75/645380	2/22/99	2372335	08/01/00	Registered; 8 & 16 due	8/1/05	08/01/10	Nexell

TRADEMARK

REEL: 004826 FRAME: 0515

NEXELL THERAPEUTICS INC.
Trademark Portfolio

OWD Docket No.	Mark	Country	Class	Goods	Serial No.	Filing Date	Reg. No.	Reg. Date	status	due date	Expiration Date	Assign Status
16635-59	NEXELL Logo	Australia	5, 10, 42	Therapeutic devices for the separation, selection, and/or modification of cells, chemical products and reagents, biological products and biological by-products, biological tissue and cells intended for subsequent implantation, or diagnostic or therapeutic use.	804744	8/23/99	804744	08/23/99	renewal due 8/23/09	8/23/09	08/23/09	Nexell
16635-59	NEXELL Logo	Canada	10	Therapeutic devices for the separation, selection, and/or modification of cells, chemical products and reagents, biological products and biological by-products, biological tissue and cells intended for subsequent implantation, or diagnostic or therapeutic.	1026583	9/13/99			see 16635-55			Nexell
16635-59	NEXELL Logo	CTM	5, 10, 42	Therapeutic devices for the separation, selection, and/or modification of cells, chemical products and reagents, biological products and biological by-products, biological tissue and cells intended for subsequent implantation, or diagnostic or therapeutic	1299262	9/6/99			Foreign associate awaiting further communication from CTM office as of 09/20/99; status			Nexell
16635-59	NEXELL Logo	Japan	5, 10, 42	Therapeutic devices for the separation, selection, and/or modification of cells, chemical products and reagents, biological products and biological by-products, biological tissue and cells intended for subsequent implantation, or diagnostic or therapeutic	11-76155	9/29/99			see 16635-55			Nexell
16635-59	NEXELL Logo	US	10	Therapeutic devices for the separation, selection, and/or modification of cells, chemical products and reagents, biological products and biological by-products, biological tissue and cells intended for subsequent implantation, or diagnostic or therapeutic use.	75/645381	2/22/99	2372336	08/01/00	Registered; 8 & 16 due	8/1/05	08/01/10	Nexell
16635-60	NEXELL Logo	Australia	5, 10, 42	Therapeutic devices for the separation, selection, and/or modification of cells, chemical products and reagents, biological products and biological by-products, biological tissue and cells intended for subsequent implantation, or diagnostic or therapeutic	804743	8/23/99			issued; renewal 8/23/09	8/23/09		Nexell

NEXELL THERAPEUTICS INC.
Trademark Portfolio

OWD Docket No.	Mark	Country	Class	Goods	Serial No.	Filing Date	Reg. No.	Reg. Date	status	due date	Expiration Date	Assign Status
16635-60	NEXELL Logo	Canada	42	Therapeutic devices for the separation, selection, and/or modification of cells, chemical products and reagents, biological products and biological by-products, biological tissue and cells intended for subsequent implantation, or diagnostic or therapeutic	1028724	9/13/99			response to oa to f/a 3/8; status	3/9/02		Nexell
16635-60	NEXELL Logo	US	42	Therapeutic devices for the separation, selection, and/or modification of cells, chemical products and reagents, biological products and biological by-products, biological tissue and cells intended for subsequent implantation, or diagnostic or therapeutic use.	75/659432	3/12/99			registered; renewal 8/8/10	8/8/10		Nexell
16635-61	NEXELL Logo	Australia	5, 10, 42	Therapeutic devices for the separation, selection, and/or modification of cells, chemical products and reagents, biological products and biological by-products, biological tissue and cells intended for subsequent implantation, or diagnostic or therapeutic	804744	8/23/99	804744	08/23/99	renewal due 8/23/09	8/23/09	08/23/09	Nexell
16635-61	NEXELL Logo	Canada	42	Therapeutic devices for the separation, selection, and/or modification of cells, chemical products and reagents, biological products and biological by-products, biological tissue and cells intended for subsequent implantation, or diagnostic or therapeutic	1026582	8/23/99			response to oa to f/a 3/8; status	3/9/02		Nexell
16635-61	NEXELL Logo	CTM	5, 10, 42	Therapeutic devices for the separation, selection, and/or modification of cells, chemical products and reagents, biological products and biological by-products, biological tissue and cells intended for subsequent implantation, or diagnostic or therapeutic	1299262	9/6/99			Foreign associate awaiting further communication from CTM office as of 09/20/99; status			Nexell
16635-61	NEXELL Logo	Japan	5, 10, 42	Therapeutic devices for the separation, selection, and/or modification of cells, chemical products and reagents, biological products and biological by-products, biological tissue and cells intended for subsequent implantation, or diagnostic or therapeutic	11-76155	8/23/99			see 16635-55			Nexell

NEXELL THERAPEUTICS INC.
Trademark Portfolio

OVD Docket No	Mark	Country	Class	Goods	Serial No.	Filing Date	Reg. No.	Reg. Date	status	due date	Expiration Date	Assign Status
16635-61	NEXELL Logo	US	42	Therapeutic devices for the separation, selection, and/or modification of cells, chemical products and reagents, biological products and biological by-products, biological tissue and cells intended for subsequent implantation, or diagnostic or therapeutic use.	75/659400	3/12/99	2,374,723	08/08/00	registered; renewal 8/8/10	8/8/10	08/08/10	Nexell
16635-62	Nexell	Australia	5	Therapeutic devices for the separation, selection, and/or modification of cells, chemical products and reagents, biological products and biological by-products, biological tissue and cells intended for subsequent implantation, or diagnostic or therapeutic use.	804743	8/23/99			registered; renewal 8/23/09	8/23/09	08/23/09	Nexell
16635-62	Nexell	Canada	5, 10	Therapeutic devices for the separation, selection, and/or modification of cells, chemical products and reagents, biological products and biological by-products, biological tissue and cells intended for subsequent implantation, or diagnostic or therapeutic use.					see 16635-58			Nexell
16635-62	Nexell	US	5	Therapeutic devices for the separation, selection, and/or modification of cells, chemical products and reagents, biological products and biological by-products, biological tissue and cells intended for subsequent implantation, or diagnostic or therapeutic use.	75/645382	2/22/99	2432769	03/06/01	8 & 15 due 3/6/06	3/6/06	03/06/11	Nexell
16635-69	DiagnNex	US							application on hold			
16635-70	Cellextra	Australia	10	Medical Product, namely a cell expansion and cell manipulation device	786747	2/24/99	786747	02/26/99	02/26/09 - Taxes Due	2/26/09	02/26/09	Nexell
16635-70	Cellextra	Canada	10	Medical Product, namely a cell expansion and cell manipulation device	1006106	3/24/99			allow to lapse	//		Nexell
16635-70	Cellextra	France	10	Medical Product, namely a cell expansion and cell manipulation device	99/794663	5/21/99	99794663	05/21/99	05/21/09 - Taxes Due	5/21/09	05/21/09	Nexell
16635-70	Cellextra	Germany	10	Medical Product, namely a cell expansion and cell manipulation device	39910046/6/10	2/22/99	39910046	06/29/99	2/28/09 - Taxes Due	2/28/09	02/28/09	Nexell
16635-70	Cellextra	UK	10	Medical Product, namely a cell expansion and cell manipulation device	2190484	3/2/99	2190484	03/02/99	03/02/09 - Taxes Due	3/2/09	03/02/09	Nexell
16635-70	Cellextra	US	10	Medical Product, namely a cell expansion and cell manipulation device	75/641656	2/16/99			file Statement of Use; allow to lapse	//		Nexell

NEXELL THERAPEUTICS INC.
Trademark Portfolio

OWD Docket No.	Mark	Country	Class	Goods	Serial No.	Filing Date	Reg. No.	Reg. Date	status	due date	Expiration Date	Assign Status
16635-71	Cytorex	EC	10	Diagnostic kits, diagnostic reagents; diagnostic kits and reagents for the enrichment, detection and characterization of tumor cells	1481837	1/28/00	1481837		1/28/10 - Renewal	1/28/10	01/28/10	Nexell
16635-71	Cytonex	US	10	Diagnostic kits and reagents for the enrichment, detection and characterization of tumor cells	75/761451	7/27/99			Strnt of use 1/17/02	1/17/02		Nexell
16635-86	Optocyte	US	10	Medical devices including devices for holding, manipulating and culturing biologic products	76/131904	9/20/00			approved for publication 2/17/01; status	2/17/02		Nexell
16635-98	CYTOMA TE	US	10	Medical Devices including devices for holding, manipulating and culturing biologic products	76/227845	3/21/01			awaiting first office action	3/21/02		Nexell

TRADEMARK

REEL: 004826 FRAME: 0519

RECORDED: 07/20/2012